Cargando…

A genomic-clinical nomogram predicting recurrence-free survival for patients diagnosed with hepatocellular carcinoma

Liver resection surgery is the most commonly used treatment strategy for patients diagnosed with hepatocellular carcinoma (HCC). However, there is still a chance for recurrence in these patients despite the survival benefits of this procedure. This study aimed to explore recurrence-related genes (RR...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Junjie, Wang, Tao, Shen, Shu, Zhang, Zifei, Yang, Xianwei, Wang, Wentao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825747/
https://www.ncbi.nlm.nih.gov/pubmed/31687273
http://dx.doi.org/10.7717/peerj.7942
_version_ 1783464949501132800
author Kong, Junjie
Wang, Tao
Shen, Shu
Zhang, Zifei
Yang, Xianwei
Wang, Wentao
author_facet Kong, Junjie
Wang, Tao
Shen, Shu
Zhang, Zifei
Yang, Xianwei
Wang, Wentao
author_sort Kong, Junjie
collection PubMed
description Liver resection surgery is the most commonly used treatment strategy for patients diagnosed with hepatocellular carcinoma (HCC). However, there is still a chance for recurrence in these patients despite the survival benefits of this procedure. This study aimed to explore recurrence-related genes (RRGs) and establish a genomic-clinical nomogram for predicting postoperative recurrence in HCC patients. A total of 123 differently expressed genes and three RRGs (PZP, SPP2, and PRC1) were identified from online databases via Cox regression and LASSO logistic regression analyses and a gene-based risk model containing RRGs was then established. The Harrell’s concordance index (C-index), receiver operating characteristic (ROC) curves and calibration curves showed that the model performed well. Finally, a genomic-clinical nomogram incorporating the gene-based risk model, AJCC staging system, and Eastern Cooperative Oncology Group performance status was constructed to predict the 1-, 2-, and 3-year recurrence-free survival rates (RFS) for HCC patients. The C-index, ROC analysis, and decision curve analysis were good indicators of the nomogram’s performance. In conclusion, we identified three reliable RRGs associated with the recurrence of cancer and constructed a nomogram that performed well in predicting RFS for HCC patients. These findings could enrich our understanding of the mechanisms for HCC recurrence, help surgeons predict patients’ prognosis, and promote HCC treatment.
format Online
Article
Text
id pubmed-6825747
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher PeerJ Inc.
record_format MEDLINE/PubMed
spelling pubmed-68257472019-11-04 A genomic-clinical nomogram predicting recurrence-free survival for patients diagnosed with hepatocellular carcinoma Kong, Junjie Wang, Tao Shen, Shu Zhang, Zifei Yang, Xianwei Wang, Wentao PeerJ Bioinformatics Liver resection surgery is the most commonly used treatment strategy for patients diagnosed with hepatocellular carcinoma (HCC). However, there is still a chance for recurrence in these patients despite the survival benefits of this procedure. This study aimed to explore recurrence-related genes (RRGs) and establish a genomic-clinical nomogram for predicting postoperative recurrence in HCC patients. A total of 123 differently expressed genes and three RRGs (PZP, SPP2, and PRC1) were identified from online databases via Cox regression and LASSO logistic regression analyses and a gene-based risk model containing RRGs was then established. The Harrell’s concordance index (C-index), receiver operating characteristic (ROC) curves and calibration curves showed that the model performed well. Finally, a genomic-clinical nomogram incorporating the gene-based risk model, AJCC staging system, and Eastern Cooperative Oncology Group performance status was constructed to predict the 1-, 2-, and 3-year recurrence-free survival rates (RFS) for HCC patients. The C-index, ROC analysis, and decision curve analysis were good indicators of the nomogram’s performance. In conclusion, we identified three reliable RRGs associated with the recurrence of cancer and constructed a nomogram that performed well in predicting RFS for HCC patients. These findings could enrich our understanding of the mechanisms for HCC recurrence, help surgeons predict patients’ prognosis, and promote HCC treatment. PeerJ Inc. 2019-10-31 /pmc/articles/PMC6825747/ /pubmed/31687273 http://dx.doi.org/10.7717/peerj.7942 Text en © 2019 Kong et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
spellingShingle Bioinformatics
Kong, Junjie
Wang, Tao
Shen, Shu
Zhang, Zifei
Yang, Xianwei
Wang, Wentao
A genomic-clinical nomogram predicting recurrence-free survival for patients diagnosed with hepatocellular carcinoma
title A genomic-clinical nomogram predicting recurrence-free survival for patients diagnosed with hepatocellular carcinoma
title_full A genomic-clinical nomogram predicting recurrence-free survival for patients diagnosed with hepatocellular carcinoma
title_fullStr A genomic-clinical nomogram predicting recurrence-free survival for patients diagnosed with hepatocellular carcinoma
title_full_unstemmed A genomic-clinical nomogram predicting recurrence-free survival for patients diagnosed with hepatocellular carcinoma
title_short A genomic-clinical nomogram predicting recurrence-free survival for patients diagnosed with hepatocellular carcinoma
title_sort genomic-clinical nomogram predicting recurrence-free survival for patients diagnosed with hepatocellular carcinoma
topic Bioinformatics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825747/
https://www.ncbi.nlm.nih.gov/pubmed/31687273
http://dx.doi.org/10.7717/peerj.7942
work_keys_str_mv AT kongjunjie agenomicclinicalnomogrampredictingrecurrencefreesurvivalforpatientsdiagnosedwithhepatocellularcarcinoma
AT wangtao agenomicclinicalnomogrampredictingrecurrencefreesurvivalforpatientsdiagnosedwithhepatocellularcarcinoma
AT shenshu agenomicclinicalnomogrampredictingrecurrencefreesurvivalforpatientsdiagnosedwithhepatocellularcarcinoma
AT zhangzifei agenomicclinicalnomogrampredictingrecurrencefreesurvivalforpatientsdiagnosedwithhepatocellularcarcinoma
AT yangxianwei agenomicclinicalnomogrampredictingrecurrencefreesurvivalforpatientsdiagnosedwithhepatocellularcarcinoma
AT wangwentao agenomicclinicalnomogrampredictingrecurrencefreesurvivalforpatientsdiagnosedwithhepatocellularcarcinoma
AT kongjunjie genomicclinicalnomogrampredictingrecurrencefreesurvivalforpatientsdiagnosedwithhepatocellularcarcinoma
AT wangtao genomicclinicalnomogrampredictingrecurrencefreesurvivalforpatientsdiagnosedwithhepatocellularcarcinoma
AT shenshu genomicclinicalnomogrampredictingrecurrencefreesurvivalforpatientsdiagnosedwithhepatocellularcarcinoma
AT zhangzifei genomicclinicalnomogrampredictingrecurrencefreesurvivalforpatientsdiagnosedwithhepatocellularcarcinoma
AT yangxianwei genomicclinicalnomogrampredictingrecurrencefreesurvivalforpatientsdiagnosedwithhepatocellularcarcinoma
AT wangwentao genomicclinicalnomogrampredictingrecurrencefreesurvivalforpatientsdiagnosedwithhepatocellularcarcinoma